Antiparkinsonian activity of L‐propyl‐L‐leucyl‐glycinamide or melanocyte‐inhibiting factor in MPTP‐treated common marmosets
Identifieur interne : 003018 ( Main/Exploration ); précédent : 003017; suivant : 003019Antiparkinsonian activity of L‐propyl‐L‐leucyl‐glycinamide or melanocyte‐inhibiting factor in MPTP‐treated common marmosets
Auteurs : Regina Katzenschlager [Royaume-Uni, Autriche] ; Michael J. Jackson [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Kim Stockwell [Royaume-Uni] ; Kayhan A. Tayarani-Binazir [Royaume-Uni] ; Mohammed Zubair [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Peter Jenner [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-04-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Administration, Oral, Animals, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (toxicity), Benserazide (administration & dosage), Benserazide (toxicity), Callithrix, Dose-Response Relationship, Drug, Drug Therapy, Combination, Dyskinesia, Female, Infusions, Intravenous, Levodopa (administration & dosage), Levodopa (toxicity), Locomotion (drug effects), MSH Release-Inhibiting Hormone (administration & dosage), MSH Release-Inhibiting Hormone (toxicity), Male, Motor Activity (drug effects), Nervous system diseases, Parkinson disease, Parkinson's disease, Parkinsonian Disorders (drug therapy), Treatment, dyskinesia, marmoset, melanocyte‐inhibiting factor (MIF).
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Benserazide, Levodopa, MSH Release-Inhibiting Hormone.
- chemical , toxicity : Antiparkinson Agents, Benserazide, Levodopa, MSH Release-Inhibiting Hormone.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- drug effects : Locomotion, Motor Activity.
- drug therapy : Parkinsonian Disorders.
- Administration, Oral, Animals, Callithrix, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Infusions, Intravenous, Male.
Abstract
The neuropeptide melanocyte‐inhibiting factor (MIF) or L‐propyl‐L‐leucyl‐glycinamide (PLG) has been reported in some studies to improve the motor signs of Parkinson's disease (PD) and in rodent models of PD. In this study of oral and intravenous MIF in N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐lesioned marmosets, a wide range of doses of MIF administered alone (0.25, 1, 2, 5, 10, 20 mg/kg orally) did not increase locomotor activity, relieve motor disability, or induce dyskinesias. When MIF (1.0 and 5.0 mg/kg orally or 10 and 20 mg/kg intravenously) was administered concomitantly with levodopa/benserazide, no significant differences in motor function or dyskinesias were observed compared with levodopa/benserazide alone. The results of this first study of MIF in the marmoset MPTP model provide no encouragement for the reinvestigation of MIF in the clinical management of the motor signs of PD. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21256
Affiliations:
- Autriche, Royaume-Uni
- Angleterre, Grand Londres, Vienne (Autriche)
- Londres, Vienne (Autriche)
- National Hospital for Neurology and Neurosurgery
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002934
- to stream Istex, to step Curation: 002934
- to stream Istex, to step Checkpoint: 001B26
- to stream PubMed, to step Corpus: 002806
- to stream PubMed, to step Curation: 002806
- to stream PubMed, to step Checkpoint: 002975
- to stream Ncbi, to step Merge: 001B33
- to stream Ncbi, to step Curation: 001B33
- to stream Ncbi, to step Checkpoint: 001B33
- to stream Main, to step Merge: 003F40
- to stream PascalFrancis, to step Corpus: 001715
- to stream PascalFrancis, to step Curation: 001606
- to stream PascalFrancis, to step Checkpoint: 001794
- to stream Main, to step Merge: 004384
- to stream Main, to step Curation: 003018
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiparkinsonian activity of L‐propyl‐L‐leucyl‐glycinamide or melanocyte‐inhibiting factor in MPTP‐treated common marmosets</title><author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name></author><author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name></author><author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name></author><author><name sortKey="Stockwell, Kim" sort="Stockwell, Kim" uniqKey="Stockwell K" first="Kim" last="Stockwell">Kim Stockwell</name></author><author><name sortKey="Tayarani Inazir, Kayhan A" sort="Tayarani Inazir, Kayhan A" uniqKey="Tayarani Inazir K" first="Kayhan A." last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name></author><author><name sortKey="Zubair, Mohammed" sort="Zubair, Mohammed" uniqKey="Zubair M" first="Mohammed" last="Zubair">Mohammed Zubair</name></author><author><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name><affiliation><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName>National Hospital for Neurology and Neurosurgery</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3A0D5F157B0A593D17D43EB7E889F5189630C0AD</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21256</idno><idno type="url">https://api.istex.fr/document/3A0D5F157B0A593D17D43EB7E889F5189630C0AD/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002934</idno><idno type="wicri:Area/Istex/Curation">002934</idno><idno type="wicri:Area/Istex/Checkpoint">001B26</idno><idno type="wicri:doubleKey">0885-3185:2007:Katzenschlager R:antiparkinsonian:activity:of</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17373723</idno><idno type="wicri:Area/PubMed/Corpus">002806</idno><idno type="wicri:Area/PubMed/Curation">002806</idno><idno type="wicri:Area/PubMed/Checkpoint">002975</idno><idno type="wicri:Area/Ncbi/Merge">001B33</idno><idno type="wicri:Area/Ncbi/Curation">001B33</idno><idno type="wicri:Area/Ncbi/Checkpoint">001B33</idno><idno type="wicri:doubleKey">0885-3185:2007:Katzenschlager R:antiparkinsonian:activity:of</idno><idno type="wicri:Area/Main/Merge">003F40</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:07-0263042</idno><idno type="wicri:Area/PascalFrancis/Corpus">001715</idno><idno type="wicri:Area/PascalFrancis/Curation">001606</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001794</idno><idno type="wicri:doubleKey">0885-3185:2007:Katzenschlager R:antiparkinsonian:activity:of</idno><idno type="wicri:Area/Main/Merge">004384</idno><idno type="wicri:Area/Main/Curation">003018</idno><idno type="wicri:Area/Main/Exploration">003018</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Antiparkinsonian activity of L‐propyl‐L‐leucyl‐glycinamide or melanocyte‐inhibiting factor in MPTP‐treated common marmosets</title><author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, University College London, United Kingdom and National Hospital for Neurology and Neurosurgery, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Donauspital/SMZ‐Ost, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College London</wicri:regionArea><wicri:noRegion>King's College London</wicri:noRegion></affiliation></author><author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College London</wicri:regionArea><wicri:noRegion>King's College London</wicri:noRegion></affiliation></author><author><name sortKey="Stockwell, Kim" sort="Stockwell, Kim" uniqKey="Stockwell K" first="Kim" last="Stockwell">Kim Stockwell</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College London</wicri:regionArea><wicri:noRegion>King's College London</wicri:noRegion></affiliation></author><author><name sortKey="Tayarani Inazir, Kayhan A" sort="Tayarani Inazir, Kayhan A" uniqKey="Tayarani Inazir K" first="Kayhan A." last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College London</wicri:regionArea><wicri:noRegion>King's College London</wicri:noRegion></affiliation></author><author><name sortKey="Zubair, Mohammed" sort="Zubair, Mohammed" uniqKey="Zubair M" first="Mohammed" last="Zubair">Mohammed Zubair</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College London</wicri:regionArea><wicri:noRegion>King's College London</wicri:noRegion></affiliation></author><author><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College London</wicri:regionArea><wicri:noRegion>King's College London</wicri:noRegion></affiliation></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College London</wicri:regionArea><wicri:noRegion>King's College London</wicri:noRegion></affiliation></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, University College London, United Kingdom and National Hospital for Neurology and Neurosurgery, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName>National Hospital for Neurology and Neurosurgery</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-04-15">2007-04-15</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="715">715</biblScope><biblScope unit="page" to="719">719</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">3A0D5F157B0A593D17D43EB7E889F5189630C0AD</idno><idno type="DOI">10.1002/mds.21256</idno><idno type="ArticleID">MDS21256</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Administration, Oral</term><term>Animals</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (toxicity)</term><term>Benserazide (administration & dosage)</term><term>Benserazide (toxicity)</term><term>Callithrix</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Dyskinesia</term><term>Female</term><term>Infusions, Intravenous</term><term>Levodopa (administration & dosage)</term><term>Levodopa (toxicity)</term><term>Locomotion (drug effects)</term><term>MSH Release-Inhibiting Hormone (administration & dosage)</term><term>MSH Release-Inhibiting Hormone (toxicity)</term><term>Male</term><term>Motor Activity (drug effects)</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Parkinsonian Disorders (drug therapy)</term><term>Treatment</term><term>dyskinesia</term><term>marmoset</term><term>melanocyte‐inhibiting factor (MIF)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Benserazide</term><term>Levodopa</term><term>MSH Release-Inhibiting Hormone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Antiparkinson Agents</term><term>Benserazide</term><term>Levodopa</term><term>MSH Release-Inhibiting Hormone</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Locomotion</term><term>Motor Activity</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Animals</term><term>Callithrix</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Female</term><term>Infusions, Intravenous</term><term>Male</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term><term>Parkinson maladie</term><term>Système nerveux pathologie</term><term>Traitement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The neuropeptide melanocyte‐inhibiting factor (MIF) or L‐propyl‐L‐leucyl‐glycinamide (PLG) has been reported in some studies to improve the motor signs of Parkinson's disease (PD) and in rodent models of PD. In this study of oral and intravenous MIF in N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐lesioned marmosets, a wide range of doses of MIF administered alone (0.25, 1, 2, 5, 10, 20 mg/kg orally) did not increase locomotor activity, relieve motor disability, or induce dyskinesias. When MIF (1.0 and 5.0 mg/kg orally or 10 and 20 mg/kg intravenously) was administered concomitantly with levodopa/benserazide, no significant differences in motor function or dyskinesias were observed compared with levodopa/benserazide alone. The results of this first study of MIF in the marmoset MPTP model provide no encouragement for the reinvestigation of MIF in the clinical management of the motor signs of PD. © 2007 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Autriche</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li><li>Vienne (Autriche)</li></region><settlement><li>Londres</li><li>Vienne (Autriche)</li></settlement><orgName><li>National Hospital for Neurology and Neurosurgery</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name></region><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name><name sortKey="Stockwell, Kim" sort="Stockwell, Kim" uniqKey="Stockwell K" first="Kim" last="Stockwell">Kim Stockwell</name><name sortKey="Tayarani Inazir, Kayhan A" sort="Tayarani Inazir, Kayhan A" uniqKey="Tayarani Inazir K" first="Kayhan A." last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name><name sortKey="Zubair, Mohammed" sort="Zubair, Mohammed" uniqKey="Zubair M" first="Mohammed" last="Zubair">Mohammed Zubair</name></country><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003018 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003018 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:3A0D5F157B0A593D17D43EB7E889F5189630C0AD
|texte= Antiparkinsonian activity of L‐propyl‐L‐leucyl‐glycinamide or melanocyte‐inhibiting factor in MPTP‐treated common marmosets
}}
| This area was generated with Dilib version V0.6.23. |  |